Alector shares rose 21.5% to $2.19 after Roche signed a license agreement worth up to $1.27 billion for the company's Parkinson's disease treatments.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.